Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
28th September 2022
Portfolio
This post references, or is about Aura. Find out more by clicking below